NEW YORK – Natera and Personalis said on Wednesday that they are partnering on cancer treatment monitoring and molecular residual disease (MRD) testing.
Under the non-exclusive agreement, Natera will use matched tumor and normal exome sequencing data generated by Personalis to validate the design of its Signatera personalized circulating tumor DNA assays. The deal covers MRD testing for both clinical and research use and Natera will be responsible for commercializing the assays.
Personalis offers the NeXT Exome, which enhances conventional exome assays by adding coverage across coding regions and by including additional genomic regions.
"This represents another step forward in Natera's vision for Signatera, as a personalized monitoring and MRD platform that can be scaled and integrated robustly with high-quality, exome-scale tissue sequencing assays worldwide, of which Personalis' NeXT is a leading example," Solomon Moshkevich, Natera's general manager of oncology, said in a statement, adding that Natera hopes to expand access to Signatera to a new set of customers through the deal.
Financial and other terms of the agreement were not disclosed.